Li Fraumeni syndrome, due to TP53 mutations, also is more prevalent in early-onset HR-/HER2+ breast cancer [42], but the incidence of this disease is not known to differ by race/ethnicity [39]. This evidence concerns the gene ERBB2 and breast carcinoma.